盐酸莫西沙星氯化钠注射液治疗下呼吸道感染患者的药动学及药效学分析

Abstract
Figure/Table
References (15)
Related Citation (11)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the pharmacokinetics and pharmacodynamics of Moxifloxacin Hydrochloride and Sodium Chloride Injection in patients with lower respiratory tract infection (LRTI). Methods Seventy-six LRTI patients admitted to Jiujiang First People′s Hospital from March 2019 to March 2021 were selected as the study subjects. All patients received intravenous infusion of moxifloxacin hydrochloride and sodium chloride injection. Blood concentration of moxifloxacin (Mox) was determined by high performance liquid chromatography, and minimum inhibitory concentration (MIC) of bacteria was determined by broth dilution method. The therapeutic effect, etiological efficacy, plasma concentration of Mox and MIC of pathogenic bacteria were observed. Results The total effective rate of 76 patients was 89.47% (68/76), among which the total effective rate of 36 patients with pneumonia was up to 100.00% (36/36). Before treatment, 76 strains of pathogenic bacteria were detected in 76 patients, among which Mycoplasma pneumoniae had the highest detection rate, followed by Staphylococcus aureus. The clearance rate of pathogenic bacteria after treatment was 90.79% (69/76). After single dose, Mox peak concentration, trough concentration and steady-state plasma concentration were (4.25±0.06) mg/L, (1.44±0.08) mg/L and (3.67±0.05) mg/L, respectively. Mox showed good sensitivity to Mycoplasma pneumoniae and Streptococcus pneumoniae, with MIC of 0.25 mg/L. Mox had poor sensitivity to Staphylococcus aureus. Conclusion Moxifloxacin hydrochloride and sodium chloride injection has a better therapeutic effect in LRTI patients, which can achieve effective therapeutic concentration and remove pathogenic bacteria.

Key words： Lower respiratory tract infection Moxifloxacin hydrochloride and sodium chloride injection Pharmacokinetics Pharmacodynamics

Received: 25 May 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/43

[1]	徐敏，胡岗，刘晓，等.头孢哌酮/舒巴坦联合莫西沙星治疗COPD 合并急性下呼吸道感染临床疗效及对血清相关因子的影响[J].西部医学，2019，31（3）：416-421.
[2]	苏梅香.肺结核经过莫西沙星治疗和康复训练的疗效观察[J].中国地方病防治杂志，2019，34（6）：718，720.
[3]	赵嘉，韩朋飞，张丽.美罗培南联合莫西沙星对COPD 并发感染性肺炎患者肺功能的影响[J].贵州医药，2018，42（5）：585-586.
[4]	卜兰英，吕弘道，王利明，等.乳糖酸阿奇霉素联合莫西沙星对淋球菌感染患者血清IgG 和IgM 指标的影响[J].中华医院感染学杂志，2019，29（9）：1297-1300.
[5]	中华人民共和国卫生部.医院感染诊断标准（试行）[J].中华医学杂志，2001，81（5）：314-320.
[6]	中华医学会.抗菌药物临床应用指导原则[J].中国实用眼科杂志，2008，26（7）：487-487.
[7]	季洪健，王辉，姚秋菊.新兵集训呼吸道传染病防控的健康教育[J].解放军医院管理杂志，2018，25（12）：1161-1162，1165.
[8]	冯伟，朱海蓉，姚永国，等.驻西北某部新训机构冬季呼吸道传染病防治现状与对策建议[J].解放军预防医学杂志，2020，38（3）：96-97，116.
[9]	曲雪红，万春霞，张伶俐.沿海地区ICU 患者下呼吸道感染病原菌分布、疑难菌鉴定及耐药性分析[J].中华航海医学与高气压医学杂志，2019，26（2）：159-161.
[10]	黄少隆，黄冬枚，郭文婷，等.虎门地区老年人肺部感染病原菌的分布及耐药性[J].检验医学与临床，2020，17（10）：1366-1369，1372.
[11]	董燕，陈俊文，阳俊，等.莫西沙星与头孢哌酮舒巴坦治疗老年心力衰竭患者铜绿假单胞菌院内感染的疗效对比观察[J].安徽医药，2018，22（2）：312-315.
[12]	顾贝欣，吴建博，沈杰，等.莫西沙星注射液相关的老年呼吸系统感染患者低钾血症危险因素分析[J].中国感染与化疗杂志，2020，20（5）：502-505.
[13]	贾晓佳.莫西沙星溶液雾化吸入治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果及对机体相关指标的影响[J].中国医药，2019，14（7）：984-987.
[14]	黄娴，刘国栋，朱祥，等.头孢哌酮舒巴坦联合莫西沙星治疗老年肺部感染的临床效果研究[J].现代生物医学进展，2018，18（15）：2886-2889.
[15]	孙婉.盐酸莫西沙星氯化钠注射液治疗下呼吸道感染的药动学和药效学分析[J].中国医药指南，2017，15（8）：172-173.